Adaptive Phage Therapeutics Enters Into Definitive Merger Agreement With BiomX

Reston – March 6, 2024 – Cooley advised Adaptive Phage Therapeutics (APT), a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX (NYSE: PHGE), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria. Lawyers Christian Plaza, Matthew Silverman, Brian Leaf, Matthew Schwee, Joyce Li and Rasha Printz led the Cooley team advising APT.

Immediately after the effective date of the merger, BiomX will own approximately 55%, and the former stockholders of APT will own approximately 45%, of the consolidated entity of BiomX and APT. The merger is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.